Jazz Pharmaceuticals


Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America.

Company history & Acquisitions

2010

On February 18, the FDA accepted a new drug application for JZP-6 for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.

2011

On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge.

2012

On April 26, the company acquired EUSA Pharma for $650 million. In September the company successfully sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia.

2014

In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.

2016

In May, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its largest acquisition to date, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos for treatment of acute myeloid leukemia.

2019

In August the company announced it would acquire Cavion Inc. for up to ~$310 million.

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors :